140 related articles for article (PubMed ID: 30035788)
21. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?
Aoyama T; Takano M; Miyamoto M; Yoshikawa T; Soyama H; Kato K; Ishibashi H; Iwahashi H; Nakatsuka M; Yajima I; Shimizu Y; Aizawa Y; Suguchi Y; Moriiwa M; Goto T; Sasa H; Nagaoka I; Tsuda H; Furuya K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):65-69. PubMed ID: 28493032
[TBL] [Abstract][Full Text] [Related]
22. Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions.
Lofy M; Jung L; Dow-Hillgartner E
J Oncol Pharm Pract; 2024 Mar; 30(2):412-416. PubMed ID: 37936371
[TBL] [Abstract][Full Text] [Related]
23. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel pre-medication: A comparison of two steroid pre-medication protocols.
Yenilmez A; Hood AP; Nguyen LH; Merl MY
J Oncol Pharm Pract; 2017 Oct; 23(7):491-495. PubMed ID: 27530242
[TBL] [Abstract][Full Text] [Related]
25. [Clinical analysis of premedication regimen with dexamethasone at different doses for docetaxel-induced hypersensitivity reaction].
Zhang MJ; Chen ZD; Pan YY
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):795. PubMed ID: 20021838
[No Abstract] [Full Text] [Related]
26. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
Yun H; Xie F; Beyl RN; Chen L; Lewis JD; Saag KG; Curtis JR
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1526-1534. PubMed ID: 27813327
[TBL] [Abstract][Full Text] [Related]
27. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
28. The effect of aprepitant and dexamethasone combination on paclitaxel-induced hypersensitivity reaction.
Yamamoto T; Natio M; Hara S; Kudo T; Miwa Y
Eur J Gynaecol Oncol; 2016; 37(6):833-836. PubMed ID: 29943931
[TBL] [Abstract][Full Text] [Related]
29. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial assessing the utility of a test-dose program with taxanes.
Stanford BL; Shah SR; Ballard EE; Jumper CA; Rabinowitz I; Dowell JE; Hunt WC; Krieger JA
Curr Med Res Opin; 2005 Oct; 21(10):1611-6. PubMed ID: 16238901
[TBL] [Abstract][Full Text] [Related]
32. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
[TBL] [Abstract][Full Text] [Related]
33. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
34. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
35. Prevention and handling of acute allergic and infusion reactions in oncology.
Joerger M
Ann Oncol; 2012 Sep; 23 Suppl 10():x313-9. PubMed ID: 22987983
[TBL] [Abstract][Full Text] [Related]
36. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
37. Incidence of infusion-related reaction to monoclonal antibody rituximab: a national kidney and transplant institute experience.
Montoya JE; Luna HG; Vergara NG; Amparo JR; Cristal-Luna GR
Ann Acad Med Singap; 2012 Mar; 41(3):125-6. PubMed ID: 22538739
[No Abstract] [Full Text] [Related]
38. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
39. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases.
Soyer O; Demir S; Bilginer Y; Batu ED; Sonmez HE; Arıcı ZS; Şahiner ÜM; Sekerel BE; Ozen S
Pediatr Allergy Immunol; 2019 Dec; 30(8):833-840. PubMed ID: 31419311
[TBL] [Abstract][Full Text] [Related]
40. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
